Han Changho, Chatterjee Arindam, Noetzel Meredith J, Panarese Joseph D, Smith Emery, Chase Peter, Hodder Peter, Niswender Colleen, Conn P Jeffrey, Lindsley Craig W, Stauffer Shaun R
Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Vanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, TN 37232, USA.
The Scripps Research Institutes Molecular Screening Center, Department of Molecular Therapeutics, The Scripps Research Institute, Scripps Florida, Jupiter, Florida, USA.
Bioorg Med Chem Lett. 2015 Jan 15;25(2):384-8. doi: 10.1016/j.bmcl.2014.11.011. Epub 2014 Nov 18.
Results from a 2012 high-throughput screen of the NIH Molecular Libraries Small Molecule Repository (MLSMR) against the human muscarinic receptor subtype 1 (M1) for positive allosteric modulators is reported. A content-rich screen utilizing an intracellular calcium mobilization triple-addition protocol allowed for assessment of all three modes of pharmacology at M1, including agonist, positive allosteric modulator, and antagonist activities in a single screening platform. We disclose a dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-one hit (DBPQ, CID 915409) and examine N-benzyl pharmacophore/SAR relationships versus previously reported quinolin-3(5H)-ones and isatins, including ML137. SAR and consideration of recently reported crystal structures, homology modeling, and structure-function relationships using point mutations suggests a shared binding mode orientation at the putative common allosteric binding site directed by the pendant N-benzyl substructure.
报道了2012年美国国立卫生研究院分子文库小分子储存库(MLSMR)针对人毒蕈碱受体亚型1(M1)进行的高通量筛选以寻找正变构调节剂的结果。利用细胞内钙动员三重添加方案进行的内容丰富的筛选允许在单一筛选平台上评估M1的所有三种药理学模式,包括激动剂、正变构调节剂和拮抗剂活性。我们公开了一种二苄基-2H-吡唑并[4,3-c]喹啉-3(5H)-酮命中化合物(DBPQ,化合物识别号915409),并研究了N-苄基药效团/构效关系,对比了先前报道的喹啉-3(5H)-酮和异吲哚酮,包括ML137。构效关系以及对最近报道的晶体结构、同源建模和使用点突变的结构-功能关系的考虑表明,由侧链N-苄基亚结构引导的假定共同变构结合位点存在共同的结合模式取向。